Luke Evnin, Director at Werewolf Therapeutics, Inc. (HOWL), sold 139,803 shares at $0.47 ($64K) on 2026-06-01, disclosed to the SEC on 2026-06-03.
Scheduled sale ($64k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.47 | 80,459 | $38K | 59.4% |
| 2 | $0.45 | 29,595 | $13K | 20.9% |
| 3 | $0.42 | 29,749 | $12K | 19.6% |
| Total | $0.46 avg | 139,803 | $64K | 100% |
| Filing → |
| HOWL | SELL | 2026-06-10 | $28K | — | Filing → |
| HOWL | SELL | 2026-06-08 | $43K | — | Filing → |
| HOWL | SELL | 2026-05-29 | $66K | — | Filing → |